Summit Therapeutics Inc. share price logo

Summit Therapeutics Inc.

NASDAQ: SMMT

Large Cap

$15.10

-0.02

(-0.10%)

as on

Summit Therapeutics Inc. Stock Performance

as on August 13, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $14.99
    $15.75
    downward going graph

    0.73%

    Downside

    4.30%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $12.25
    $30.05
    downward going graph

    18.87%

    Downside

    99.01%

    Upside

    downward going graph

Summit Therapeutics Inc. share price movements today

Previous Close
$15.12
Open
$15.41
Volume
3.0M
Day's Low - High
$14.99 - $15.75
52 Week Low - High
$12.25 - $30.05

Summit Therapeutics Inc. Historical Returns

1 Month Return
-1.21 %
3 Month Return
-19.56 %
1 Year Return
-43.75 %
3 Year Return
+ 778.78 %
5 Year Return
+ 90.85 %

Summit Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Summit Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.9B

EPS (TTM)

-0.8598

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-874.7M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-192.51%

Summit Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$11.9B90.85%NA0.00%NA
BUY$44.4B704.19%NA0.00%NA
BUY$132.8B172.51%28.935.00%NA
BUY$83.2B27.56%19.4227.87%0.45999999999999996%

Stock Returns calculator for Summit Therapeutics Inc. Stock including INR - Dollar returns

The Summit Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Summit Therapeutics Inc. investment value today

Current value as on today

₹61,145

Returns

-₹38,855

(-38.86%)

Returns from Summit Therapeutics Inc. Stock

-₹43,803 (-43.8%)

Dollar Impact

₹4,948 (+4.95%)

Analyst Recommendation on Summit Therapeutics Inc. Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc.. Average target price of $28.44

Summit Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Summit Therapeutics Inc..

What analysts predicted

46.91%UPSIDE

Target Price

$28.44

Current Price

$15.1

Analyzed by

7 Analysts

Target

$28.44

Summit Therapeutics Inc. target price $28.44, a slight upside of 46.91% compared to current price of $15.1. According to 7 analysts rating.

Indian Investors' Interest in Summit Therapeutics Inc. Stock

Investment in Summit Therapeutics Inc. Shares on INDmoney has grown by 70.45% in the last 30 days, indicating increased investment activity.

Time period: to

Change:70.45% versus previous 30 day period

Search interest for Summit Therapeutics Inc. Stock has decreased by -26% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-26% versus previous 30 day period

Summit Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
-18
0
0
-
0
0
-
Operating Income
-47
-43
-52
-51
-234
-234
-224
-195
-220
EBITDA
-35
-39
-48
-48
-231
-
-219
-189
-215
Interest Expense
3
2
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-47
-42
-48
-48
-231
-231
-219
-189
-215
Income Tax Expense
0
0
0
-
-
-
-
-
-
Net Income
-60
-55
-61
-62
-231
-231
-219
-189
-215
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Summit Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Jan 2021
Dec 2021
Jan 2022
Dec 2022
Jan 2023
Dec 2023
Jan 2024
Dec 2024
Dec 2025
Total Revenue
0
1
2
2
0
0
-
-
-
-
Gross Profit
0
-
2
-
0
-
-2
-
-18
0
Operating Income
-71
-
-86
-
-59
-
-478
-
-180
-1,094
EBITDA
-37
-
-83
-
-51
-
-69
-
-168
-1,079
Interest Expense
0
-
0
-
4
-
16
-
8
-
Depreciation
2
-
2
-
2
-
2
-
0
0
Income Before Tax
-62
-
-88
-
-65
-
-482
-
-176
-1,079
Income Tax Expense
-9
-
-2
-
-4
-
0
-
0
-
Net Income
-51
-71
-114
-116
-79
-90
-610
-614
-223
-1,079
Net Profit Margin
-6127.56%
-6127.56%
-4762.13%
-4762.13%
-11174.75%
-10561.06%
0.00%
0.00%
0.00%
0.00%

Summit Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-47
-42
-48
-48
-172
-173
-162
-143
-261
Operating Cash Flow
-26
-23
-38
-47
-69
-93
-75
-92
-167
Investing Cash Flow
-158
-82
66
124
0
-
-360
0
222
Financing Cash Flow
158
155
-18
5
25
33
425
2
456
Change in Cash
-25
49
8
82
-44
-59
-9
-90
511

Summit Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-33
10
-23
-38
-65
-64
-486
-176
-801
Operating Cash Flow
-20
-35
-26
-35
-53
-33
-60
-113
-239
Investing Cash Flow
-7
0
0
0
0
0
-465
-164
-129
Financing Cash Flow
19
44
33
37
57
505
68
304
458
Change in Cash
-11
6
6
1
3
470
-456
26
89

Global Institutional Holdings in Summit Therapeutics Inc.

Funds
Holdings
Pictet Asset Manangement SA
0.17%
OZ Management LLC
0.05%
Readystate Asset Management LP
0.04%
Polymer Capital Management (Hk) Ltd
0.18%
FMR Inc
1.36%

Summit Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 24 July

    Fri, 06:40 PM

    -

    Summit reports Q2 2026 loss per share of 28 cents, wider than estimates, with no revenues recorded.

    Fri, 09:23 PM

    -

    Summit Therapeutics flags going concern risk due to insufficient cash for operations, raising doubts about its future viability.

Insights on Summit Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, SMMT stock has moved up by 11.5%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 469.1% return, outperforming this stock by 512.9%

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
OrganisationSummit Therapeutics Inc.
Headquarters601 Brickell Key Drive, Miami, FL, United States, 33131
IndustryBiotechnology
CEOMr. Robert W. Duggan
E-voting on sharesClick here to vote

Key Management of Summit Therapeutics Inc.

Name

Title

Mr. Nathan LiaBraaten

Senior Director of Investor Relations

Dr. Wang Clow Fong ScD

Chief Biometrics Officer

Mr. Robert W. Duggan

Co-CEO & Executive Chairman

Mr. Manmeet Singh Soni CPA

COO, CFO & Director

Mr. Bhaskar Anand

Chief Accounting Officer & Head of Finance

Mr. Dave Gancarz CPA

Chief Business & Strategy Officer

Dr. Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Dr. Mahkam Zanganeh D.D.S., M.B.A.

Co-CEO, President & Director

Prof. Kay Elizabeth Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Dr. Elaine Carla Stracker J.D., Ph.D.

Chief Legal Officer

FAQs

What is Summit Therapeutics Inc. share price today?

Summit Therapeutics Inc. share price today is $15.10 as on at the close of the market. Summit Therapeutics Inc. share today touched a day high of $15.75 and a low of $14.99.

What is the 52 week high and 52 week low for Summit Therapeutics Inc. share?

Summit Therapeutics Inc. share touched a 52 week high of $30.05 on and a 52 week low of $12.25 on . Summit Therapeutics Inc. stock price today i.e. is closed at $15.10,which is 49.75% down from its 52 week high and 23.27% up from its 52 week low.

What is Summit Therapeutics Inc.'s market capitalisation today?

Summit Therapeutics Inc. market capitalisation is $0.01T as on .

How to invest in Summit Therapeutics Inc. Stock (SMMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Summit Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Summit Therapeutics Inc. Shares that will get you 0.0993 shares as per Summit Therapeutics Inc. share price of $15.10 per share as on August 13, 2026 at 8:45 am IST.

What is the minimum amount required to buy Summit Therapeutics Inc. Stock (SMMT) from India?

Indian investors can start investing in Summit Therapeutics Inc. (SMMT) shares with as little as ₹95.32 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.20 in Summit Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Summit Therapeutics Inc. share’s latest price of $15.10 as on August 13, 2026 at 8:45 am IST, you will get 0.6623 shares of Summit Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Summit Therapeutics Inc. has given to Indian investors in the last 5 years?

Summit Therapeutics Inc. stock has given 90.85% share price returns and 28.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?